Why should you register your clinical trial!

*Por que você deve registrar seu ensaio clínico!*

The system for Brazilian Registration of Clinical Trials (ReBEC) was launched in December 16, 2010. This is a national repository for studies with human beings, available at www.ensaiosclinicos.gov.br, to help transparency and dissemination of clinical trials with humans.

When you register your clinical trial on ReBEC, you make it accessible to national and international scientific communities and to society in general, who will have information about health researches involving the use of new drugs and of those already being used in our country, in addition to equipment and surgical procedures or non-drug therapies among others, helping the decision-making process of health managers and professionals.

Clinical trials registry will also decrease the so-called publication bias, that is, it will prevent that only successful trials are published, forcing the publication of clinical trials with unintended results or those where the intervention could even have been harmful.

ReBEC is the result of a joint work of the Ministry of Health, through DECIT, of the Oswaldo Cruz Foundation (FIOCRUZ) and of the Pan-American Health Organization / World Health Organization (PAHO/WHO), through the Latin-American and Caribbean Health Science Information Center (BIREME/PAHO/WHO).

The platform is based on the Open Trials system with technological development led by BIREME, being a multilingual, free, open software compatible with WHO criteria and allowing the primary registry by the countries, so that data are exported to WHO’s International Clinical Trials Registry Platform (ICTRP), reason why ReBEC registries are in Portuguese aiming at the Brazilian audience, and in English, to help their dissemination abroad.

Revista Dor, respecting World Health Organization and International Committee of Medical Journal Editors policies for clinical trials registry, and acknowledging its importance for the international dissemination of information on open access clinical trials, as from this year will give publication preference to articles generated from clinical trials previously registered in a Clinical Trials Registry Platform meeting WHO and International Committee of Medical Journal Editors requirements, which can be found in ICTRP’s http://www.who.int/ictrp/en, where the Brazilian Clinical Trials Registry (ReBEC) is included.

Irimar de Paula Posso

*Editor in Chief*